GE HealthCare initiated with a Neutral at Goldman Sachs

Goldman Sachs analyst David Roman initiated coverage of GE HealthCare with a Neutral rating and $87 price target. The firm says its thesis is balanced by confidence in end market dynamics and corresponding flow-through to GE Healthcare’s sales, offset by its earnings outlook with forecasts that “essentially track consensus.” The analyst expects the stock to largely track earnings growth, with the path to multiple expansion coming from visibility to 5%-plus sales growth or capital deployment.